Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.

Objective: Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan. The aim of this multicenter study was to assess the efficacy of the combination topotecan-lapatinib in epithelial ovarian cancer relapsing after a first line of chemotherapy.

Methods: Patients having relapsed within 6 months (n = 20) or between 6 and 12 months (n = 19) received weekly topotecan (3.

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

Purpose: Sunitinib and sorafenib are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated.

Patients And Methods: Clinical features at study entry and treatment outcomes were evaluated in patients with metastatic papillary RCC (PRCC) and chromophobe RCC (ChRCC) who received either sunitinib or sorafenib as their initial TKI treatment in five US and French institutions.

[Locally advanced prostate cancer: definition, prognosis and treatment].

According to d'Amico's criteria, high-risk localized prostate cancer are defined either by an extracapsular extension (T3 or T4), either by a high Gleason score (> 7) or a PSA rate higher than 20 ng/ml. Pelvic lymph node involvement also corresponds to locally advanced prostate cancer. Statistical models called nomograms have been developed to predict the probability of prostate cancer recurrence and are also used to define locally advanced patients.

Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.

Background: Relapses of epithelial ovarian carcinoma (EOC) have a poor prognosis. Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy.

Methods: This retrospective study aimed to describe incidence, characteristics, outcomes and prognostic factors of ILNR treated over 15 years.

Diffusely increased F-18 FDG uptake in bone marrow in a patient with acute anemia and recent erythropoietin therapy.

Diffuse uptake of F-18 fluorodeoxyglucose (FDG) by the whole skeleton has been described in case of bone marrow stimulation resulting from treatment with colony-stimulating factors (CSFs): granulocyte CSF or granulocyte-macrophage CSF. The authors describe such an aspect of diffuse FDG uptake by the bone marrow during the follow-up of rectal cancer in a patient with anemia and recently treated thrice weekly by erythropoietin. To their knowledge, such an aspect of diffuse FDG uptake by the skeleton, revealing the bone marrow stimulation by erythropoietin, has not yet been reported.